[1]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版). 实用肝脏病杂志,2019,22(02):164-171. [2]段钟平,杨云生. 终末期肝病临床营养指南. 实用肝脏病杂志,2019,22(5):624-635. [3]Kim J A, Choi K M. Sarcopenia and fatty liver disease. Hepatol Int,2019,13(6):674-687. [4]Buchard B, Boirie Y, Cassagnes L, et al. Assessment of malnutrition, sarcopenia and frailty in patients with cirrhosis: which tools should we use in clinical practice? Nutrients,2020,12(1):135-139. [5]Lee Y H, Kim S U. Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease. Hepatol Int,2020,14(1):5-7. [6]Bhanji R A, Montano-Loza A J, Watt K D. Sarcopenia in cirrhosis: looking beyond the skeletal muscle loss to see the systemic disease. Hepatology,2019,70(6):2193-2203. [7]Sarin S K, Choudhury A, Sharma M K, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update . Hepatol Int,2019[ahead of print]. [8]Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl,2012,18(10):1209-1216. [9]Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease . Clin Nutr,2019,38(2):485-521. [10]EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol,2019,70(1):172-193. [11]Carey E J, Lai J C, Wang C W, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease . Liver Transpl,2017,23(5):625-633. [12]Nishikawa H, Shiraki M, Hiramatsu A, et al. Japan society of hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res,2016,46(10):951-963. [13]Hayashi F, Matsumoto Y, Momoki C, et al. Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis . Hepatol Res,2013,43(12):1264-1275. [14]Holecek M. Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy . Nutrition,2015,31(1):14-20. [15]Sinclair M, Gow P J, Grossmann M, et al. Review article: sarcopenia in cirrhosis-aetiology, implications and potential therapeutic interventions . Aliment Pharmacol Ther,2016,43(7):765-777. [16]Tsien C D, Mccullough A J, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol,2012,27(3):430-441. [17]Nutritional status in cirrhosis. Italian multicentre cooperative project on nutrition in liver cirrhosis . J Hepatol,1994,21(3):317-325. [18]Dasarathy J, Mccullough A J, Dasarathy S. Sarcopenia in alcoholic liver disease: Clinical and molecular advances . Alcohol Clin Exp Res,2017,41(8):1419-1431. [19]Kim G, Kang S H, Kim M Y, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis . PLoS One,2017,12(10):e186990. [20]Tanaka M, Okada H, Hashimoto Y, et al. Relationship between nonalcoholic fatty liver disease and muscle quality as well as quantity evaluated by computed tomography. Liver Int,2020,40(1):120-130. |